| Project/Area Number |
24590654
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAKAI Satoshi 筑波大学, 医学医療系, 講師 (30282362)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | ｴﾝﾄﾞｾﾘﾝB型受容体 / 血管障害 / 心肥大 / 循環器疾患動物 / エンドセリン / 薬理学 / エンドセリン受容体 / 受容体遮断薬 / 受容体サブタイプ / 心血管障害 / 肺動脈性肺高血圧症 / モノクロタリンピロール / 低酸素 |
|---|
| Outline of Final Research Achievements |
In this project, the roles of endothelin (ET) -B receptors and its blockade in the pathophysiology and the development of advanced treatment in the diseases of pulmonary hypertension and cardiovascular diseases. The aim of this study was to investigate the effects of the ET receptor blockade（ET-A, -B, ET-A/-B blockade） on the vascular injury of the pulmonary and systemic arteries and the cardiomyocytes. We investigated above hypothesis in the cultured rat cardiomyocytes, rats with diabetes mellitus, rat Langendorff’s heart preparation, and the human pulmonary arterial smooth muscle cells. As for endothelin receptor blockers, BQ-123 (ET-A antagonist), A-192621 (ET -B antagonist), and SB209670 (ET-A/-B dual antagonist) were used. It was revealed that the ET -B receptor blockade might contribute to ameliorating vascular thickening in the pulmonary and systemic arteries and also to ameliorating cardiomyocyte injury.
|
